Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pembrolizumab plus temozolomide first-line study in metastatic acral melanoma
ChiCTR2100050073Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and temozolomide in acral lentiginous melanoma (ALM) and melanoma, sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective response rate. Started Nov 2021; status: recruiting.
02
Drugs
pembrolizumabtemozolomide
03
Conditions
acral lentiginous melanoma (ALM)melanoma
Beyond the preview
Go deeper on ChiCTR2100050073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050073.